NJ.H. Whitney Capital Partners, LLC (J.H. Whitney), a middle-market private equity firm, announced today that it acquired TIDI Products, LLC.
Based in Neenah, Wis., TIDI is a leading provider of disposable infection prevention products used in dental practices and in acute-care settings. The companys core products include patient gowns and draping, dental bibs and towels, tray covers, equipment covers and sheaths, and barrier products. With more than 40 years of experience in the industry, TIDI enjoys a leading market position and strong relationships with the nations leading healthcare distributors.
TIDI has worked hard to develop an industry-leading platform that delivers great service and value to our customers, says Kevin McNamara, CEO and president of TIDI. We look forward to partnering with J.H. Whitney and believe that together we can enhance the next level of growth for TIDI.
TIDI products represent the first line of defense in the fight against healthcare acquired infections a key priority in todays healthcare environment, says Brian Cherry, managing director at J.H. Whitney. We have partnered with an experienced management team with an exceptional track record of customer service and financial performance. Together we are committed to the continued growth of TIDI.
CDC HICPAC Considers New Airborne Pathogen Guidelines Amid Growing Concerns
November 18th 2024The CDC HICPAC discussed updates to airborne pathogen guidelines, emphasizing the need for masks in health care. Despite risks, the committee resisted universal masking, highlighting other mitigation strategies
Breaking the Cycle: Long COVID's Impact and the Urgent Need for Preventative Measures
November 15th 2024Masking, clean air, and vaccinations are essential in combating COVID-19 and preventing long-term impacts, as evidence mounts of long COVID's significant economic, cognitive, and behavioral effects.
The Critical Role of Rapid Diagnostics in Antibiotic Stewardship
November 6th 2024Rapid diagnostics enhance patient outcomes by enabling prompt, targeted treatments, reducing inappropriate antibiotic use, and combating antimicrobial resistance through informed clinical decisions and stewardship programs.